company mission
BioViva's mission stayed broadly stable across these two statements. In 2015, it framed itself around extending healthy human lifespan by studying the genetic basis of disease and building cellular-level therapies for degeneration and genetic disorders. The core claim was expansive: cure disease, increase resilience to cellular defects, and push physical improvement through biotechnology. By January 2016, the company sounded more focused and more ideological. The lifespan goal remained, but the mechanism came into sharper view: cellular aging as the main upstream risk factor, with gene therapy and precision medicine as the tools to regenerate tissue, fight disease, and reduce suffering. That is a shift in emphasis, from a broad biotechnology mission to a more explicit anti-aging and gene-therapy thesis. What did not change is the ambition. Both versions aim well beyond treating one disease. BioViva kept presenting itself as trying to alter the larger medical model, not just develop a narrow product. The 2016 language added two things the 2015 version did not stress as clearly: publishing research to speed the field, and a rights-based claim that people should be able to access these therapies. Evidence is thin because the sample is only two website snapshots, one year apart. That is enough to show continuity with a sharper anti-aging frame in 2016, but not enough to say the company truly changed course. This looks more like a refinement of message than a wholesale rewrite of mission.